Companies / PharmaCyte Biotech, Inc. / Activity
Activity — PharmaCyte Biotech, Inc.
10 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Jan 7, 2026 | Silverman Joshua CEO | Buy | Common Stock | $33.3K | +40K +10.63% | 416,250 3.88% of shares | low |
| Jan 6, 2026 | Silverman Joshua CEO | Buy | Common Stock | $23.7K | +30K +8.66% | 376,250 3.50% of shares | low |
| Jan 5, 2026 | Silverman Joshua CEO | Buy | Common Stock | $23.5K | +30K +9.49% | 346,250 3.23% of shares | low |
| Jan 7, 2026 | Schechter Jonathan Director | Buy | Common Stock | $16.9K | +20K +11.59% | 192,500 1.79% of shares | low |
| Jan 6, 2026 | Schechter Jonathan Director | Buy | Common Stock | $15.8K | +20K +13.11% | 172,500 1.61% of shares | low |
| Jan 5, 2026 | Schechter Jonathan Director | Buy | Common Stock | $15.6K | +20K +15.09% | 152,500 1.42% of shares | low |
| Mar 31, 2026 | Weinstein Robert Director | Grant | Stock Option (Right to Buy) | — | +119K | 119,170 1.11% of shares | low |
| Mar 31, 2026 | Walker Wayne Remell Director | Grant | Stock Option (Right to Buy) | — | +119K | 119,170 1.11% of shares | low |
| Mar 31, 2026 | Schechter Jonathan Director | Grant | Stock Option (Right to Buy) | — | +119K | 119,170 1.11% of shares | low |
| Mar 31, 2026 | Abecassis Michael M Director | Grant | Stock Option (Right to Buy) | — | +119K | 119,170 1.11% of shares | low |